Bavarian Nordic (BAVA) - Total Liabilities
Based on the latest financial reports, Bavarian Nordic (BAVA) has total liabilities worth Dkr2.00 Billion DKK (≈ $313.01 Million USD) as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore Bavarian Nordic operating cash flow efficiency to assess how effectively this company generates cash.
Bavarian Nordic - Total Liabilities Trend (2000–2024)
This chart illustrates how Bavarian Nordic's total liabilities have evolved over time, based on quarterly financial data. Check Bavarian Nordic asset resilience ratio to evaluate the company's liquid asset resilience ratio.
Bavarian Nordic Competitors by Total Liabilities
The table below lists competitors of Bavarian Nordic ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Transportadora de Gas del Sur SA B
BA:TGSU2
|
Argentina | AR$2.29 Trillion |
|
Shenzhen Kangtai Biological Products Co Ltd
SHE:300601
|
China | CN¥4.52 Billion |
|
Beijing New Oriental Star Petrochemical Engineering Co Ltd
SHE:002755
|
China | CN¥1.16 Billion |
|
SOC.BIC UNS.ADR1/2/EO382
F:BIF0
|
Germany | €948.55 Million |
|
Yunnan Shennong Agricultural Industry Group Co Ltd
SHG:605296
|
China | CN¥1.94 Billion |
|
Ziraat Gayrimenkul Yatirim Ortakligi AS
IS:ZRGYO
|
Turkey | TL11.13 Billion |
|
Kayne Anderson MLP Investment Closed Fund
NYSE:KYN
|
USA | $898.32 Million |
Liability Composition Analysis (2000–2024)
This chart breaks down Bavarian Nordic's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see BAVA market cap.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 3.84 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.15 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.13 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Bavarian Nordic's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Bavarian Nordic (2000–2024)
The table below shows the annual total liabilities of Bavarian Nordic from 2000 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | Dkr3.00 Billion ≈ $468.95 Million |
-25.32% |
| 2023-12-31 | Dkr4.01 Billion ≈ $627.91 Million |
-23.43% |
| 2022-12-31 | Dkr5.24 Billion ≈ $820.03 Million |
+11.17% |
| 2021-12-31 | Dkr4.71 Billion ≈ $737.63 Million |
+21.99% |
| 2020-12-31 | Dkr3.86 Billion ≈ $604.66 Million |
-25.41% |
| 2019-12-31 | Dkr5.18 Billion ≈ $810.70 Million |
+488.61% |
| 2018-12-31 | Dkr880.31 Million ≈ $137.73 Million |
+36.19% |
| 2017-12-31 | Dkr646.37 Million ≈ $101.13 Million |
-19.85% |
| 2016-12-31 | Dkr806.46 Million ≈ $126.18 Million |
+24.69% |
| 2015-12-31 | Dkr646.78 Million ≈ $101.19 Million |
+1.83% |
| 2014-12-31 | Dkr635.17 Million ≈ $99.38 Million |
+33.46% |
| 2013-12-31 | Dkr475.92 Million ≈ $74.46 Million |
-11.79% |
| 2012-12-31 | Dkr539.50 Million ≈ $84.41 Million |
-29.84% |
| 2011-12-31 | Dkr768.99 Million ≈ $120.31 Million |
+17.10% |
| 2010-12-31 | Dkr656.69 Million ≈ $102.74 Million |
+15.84% |
| 2009-12-31 | Dkr566.89 Million ≈ $88.69 Million |
-16.53% |
| 2008-12-31 | Dkr679.13 Million ≈ $106.26 Million |
+32.03% |
| 2007-12-31 | Dkr514.39 Million ≈ $80.48 Million |
+95.57% |
| 2006-12-31 | Dkr263.02 Million ≈ $41.15 Million |
-11.87% |
| 2005-12-31 | Dkr298.46 Million ≈ $46.70 Million |
+4.10% |
| 2004-12-31 | Dkr286.71 Million ≈ $44.86 Million |
+248.93% |
| 2003-12-31 | Dkr82.17 Million ≈ $12.86 Million |
-32.24% |
| 2002-12-31 | Dkr121.26 Million ≈ $18.97 Million |
+583.90% |
| 2001-12-31 | Dkr17.73 Million ≈ $2.77 Million |
-17.02% |
| 2000-12-31 | Dkr21.37 Million ≈ $3.34 Million |
-- |
About Bavarian Nordic
Bavarian Nordic A/S develops, manufactures, and supplies life-saving vaccines. The company offers non-replicating smallpox and monkeypox vaccines under the IMVAMUNE, IMVANEX, and JYNNEOS names; rabies vaccine for human use under the Rabipur/RabAvert name; tick-borne encephalitis vaccine under the Encepur name; Vaxchora, an oral vaccine for immunization against cholera; and Vivotif/Typhoral, an or… Read more